The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
ASAP CRN Competitive Renewal Opportunity, 2024Redefining the Pathophysiological Mechanisms of Parkinson’s Disease in the Context of Heterogeneous Neuronsl Subtypes in the Substantia Nigr
Study Rationale: The motor symptoms of Parkinson's disease (PD) result from the degeneration of dopamine-producing neurons in a brain area called the substantia nigra pars compacta (SNc). Recent...
-
ASAP CRN Competitive Renewal Opportunity, 2024Studying Basal Ganglia Networks in Parkinson's Disease
Study Rationale: People with Parkinson's disease (PD) have long been known to display remarkable motor abilities under special circumstances, such as situations that involve strong emotions or stress...
-
ASAP CRN Competitive Renewal Opportunity, 2024Mapping the LRRK2 Signaling Pathway and Uncovering Its Interplay with Other Molecular Components of Parkinson’s Disease
Study Rationale: Genetic mutations that lead to the activation of the enzyme LRRK2 are a major cause of inherited Parkinson's disease (PD). Combining the expertise of our four laboratories, we will...
-
Accelerating Biological Understanding and Therapeutic Translation For Parkinson’s Disease- Biology, 2024Establishing a Cohort of Carriers with ATP13A2 Mutations for Clinical and Biomarker Analysis
Study Rationale: Polyamines are molecules that show neuroprotective effects, and one of the genes that is mutated in Parkinson’s disease (PD), ATP13A2, regulates cellular polyamine levels. Unpublished...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Phase 2a Clinical Study of HBI-002 in Parkinson’s Disease
Study Rationale: A growing body of research suggests that low doses of carbon monoxide (CO) protect against neuronal cell loss in Parkinson’s disease (PD). Preclinical efficacy data in two rodent...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Novel Approach to Activating Glucosylceramidase in People with Parkinson’s Disease
Study Rationale: Genetic mutations resulting in a depletion of glucosylceramidase activity is the most predisposing risk factor for developing Parkinson’s disease (PD). Activating glucosylceramidase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.